ALMS
Alumis Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website alumis.com
- Employees(FY) 107
- ISIN US0223071020
Performance
-6.34%
1W
+0.84%
1M
-4.63%
3M
-4.63%
6M
-4.63%
YTD
-4.63%
1Y
Profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Recent News & Updates
- 2024-09-03 16:29
- 2024-09-03 04:29
- 2024-08-13 16:05
- 2024-08-13 04:05
- 2024-07-29 08:00
- 2024-07-28 20:00
- 2024-06-27 23:57
Alumis Announces Pricing of Initial Public Offering(GlobeNewswire)
- 2024-06-27 11:57
Alumis Announces Pricing of Initial Public Offering(Globenewswire)
Page 1 of 1
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.